INTRODUCTION {#sec1-1}
============

*Staphylococcus aureus* and its resistant form methicillin-resistant *S. aureus* (MRSA), is one of the most common nosocomial pathogens which not only causes increased morbidity and mortality but also increases the length of hospital stay and cost.\[[@ref1][@ref2]\] The health care workers (HCWs) serve as a link between hospitals, long-term care facilities, and nursing homes on one hand and the community on the other. They may serve as reservoirs, vectors, or victims of MRSA cross-transmission.\[[@ref3]\]

*S. aureus* is a member of commensal microflora and many body sites such as hands, rectum, perineum, axillae, vagina, gastrointestinal tract, and intact or inflamed skin are frequently colonized for varying time periods, and the main reservoir of MRSA is the anterior nares.\[[@ref4]\] The main sources of MRSA in the hospital environment are the asymptomatically colonized patients and HCWs.\[[@ref5]\]

The drug of choice for the treatment of serious MRSA infection is vancomycin till date.\[[@ref6]\] With the emergence of vancomycin-resistant MRSA, treatment, options have become more limited. Mupirocin, a topical glycopeptide antibiotic is now commonly used for nasal decolonization of the HCWs as part of a routine surveillance to prevent the emergence and transmission of MRSA in health care facilities.\[[@ref7]\] The increased pressure of antibiotic use has led to the emergence of mupirocin resistant *S. aureus* (MupRSA), and the clinicians are left with few alternatives to prevent the spread of MRSA.\[[@ref8]\]

The aim of the present study is to estimate the nasal carriage of MRSA as well as MupRSA among the HCWs of our hospital. Thus, a real-time prevalence of MRSA carriage and its resistance to mupirocin will help the institution to develop a better MRSA control and infection control policy by instituting use of alternative options to prevent the colonization and spread of infection in case of resistance.

METHODS {#sec1-2}
=======

Nasal swabs from HCWs working in different departments of Mayo Institute of Medical Sciences, Barabanki, Uttar Pradesh, were collected after obtaining their informed consent. Those hospitalized within the previous 1-year or on antibiotics within last 1-week of collection of the swabs were excluded from the study. Ethical clearance was obtained prior to commencement of the study. Data, including demographic profile, work profile, and medical history, were recorded in a preformed questionnaire.

Sample collection {#sec2-1}
-----------------

Nasal swabs were collected using a sterile cotton swab with transport tube. The swab was rotated in the anterior nares for 3 s. In case of sneezing, resampling was done. After collecting swabs were re-inserted in the transport tube, labeled properly, and transported to the laboratory for further processing.

Sample processing {#sec2-2}
-----------------

All the swabs were inoculated on 5% sheep blood agar and mannitol salt agar and incubated at 37°C for 24 h. After incubation, growth was identified as *S. aureus* on the basis of colony morphology, Gram stain, catalase, dimethyl sulfoxide oxidase, DNase, and coagulase test (slide and tube).

Determination of methicillin-resistant *Staphylococcus aureus* {#sec2-3}
--------------------------------------------------------------

All confirmed *S. aureus* isolates were further tested for detection of methicillin resistance by Kirby--Bauer disc diffusion method using cefoxitin 30 µg discs (HiMedia Laboratories, Mumbai, Maharashtra, India) as per Clinical and Laboratory Standards Institute (CLSI) 2013 guidelines.\[[@ref9]\] Zone of inhibition of size of ≤21 mm was taken as resistant and ≥22 mm as sensitive.

Determination of antibiotic susceptibility pattern of *Staphylococcus* {#sec2-4}
----------------------------------------------------------------------

It was done by Kirby--Bauer disc diffusion method; antibiotic discs used were penicillin (10 units), ciprofloxacin (5 µg), clindamycin (2 µg), erythromycin (15 µg), levofloxacin (5 µg), linezolid (30 µg), rifampin (5 µg), tetracycline (30 µg), and cotrimoxazole (1.25/23.75 µg). Zone diameter interpretation for determining sensitive, intermediate or resistant was done as per CLSI guidelines.\[[@ref9]\]

Determination of mupirocin resistant *Staphylococcus aureus* {#sec2-5}
------------------------------------------------------------

Mupirocin resistance was determined by Epsilometer test (E-test) using HiComb mupirocin strip and interpreted as per CLSI guidelines.\[[@ref9]\] Isolates with minimum inhibitory concentrations (MICs) ≥512 μg/ml were considered as high-level resistant (MuH), those with MICs 8--256 μg/ml were considered as low-level resistant (MuL), and with ≤4 μg/ml were considered as mupirocin sensitive.

Statistical analysis {#sec2-6}
--------------------

The results were recorded and analyzed statistically in Microsoft office Excel Sheet 2010. Chi-square test was used for statistical analysis. *P* ≤ 0.05 was considered as statistically significant.

RESULTS {#sec1-3}
=======

In the present study, 200 HCWs working in our hospital were included in the study. Out of these HCWs, 92 (46%) were females and 108 (54%) were males. The age ranged between 18 and 65 years. Of the 200 nonduplicate nasal swabs processed in the laboratory, *Staphylococcus* spp. was isolated in 162 (81%) samples which comprised of 96 (48%) *S. aureus* isolates.

[Table 1](#T1){ref-type="table"} shows the distribution of various samples on the basis of the source. HCWs of various categories such as doctor, nurse, technician, nursing orderlies, nursing student, and others (included pharmacists, receptionists, and security guards) working in our hospital were taken in nearly equal representation.

###### 

Distribution of samples on the basis of source

![](JRPP-4-182-g001)

The distribution percentage of MRSA and methicillin-sensitive *S. aureus* (MSSA) strains in the total specimens received is documented in [Table 2](#T2){ref-type="table"}. In both Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, the *P* value was determined by comparing each category of HCWs with the total number of HCWs. Of 96 *S. aureus* isolates, 28 (14%) were detected as MRSA strains. Nursing orderlies showed a higher carrier rate of MRSA as compared to other HCWs which was statistically significant (*P* \< 0.05).

###### 

Distribution of MRSA and MSSA isolates on the basis of source

![](JRPP-4-182-g002)

[Table 3](#T3){ref-type="table"} displays the antibiotic susceptibility pattern of MRSA and MSSA strains for different group of antibiotics effective primarily against the Gram-positive organism. None of MRSA isolates was sensitive to penicillin, nearly 60% were resistant to clindamycin and erythromycin and around 50% were resistant to tetracycline and cotrimoxazole. All MRSA isolates were susceptible to linezolid. MSSA isolates sensitive to penicillin were 23%, nearly 60% were sensitive to clindamycin, ciprofloxacin and levofloxacin and around 50% were sensitive to tetracycline and cotrimoxazole. All MSSA isolates were susceptible to linezolid. Resistance to most of the antibiotics was significantly associated with MRSA strains (*P* \< 0.05).

###### 

Antibiotic resistance pattern of MRSA and MSSA isolates

![](JRPP-4-182-g003)

Mupirocin resistance was seen in 4 (7%) of 28 MRSA isolates by E-test; 3 (75%) isolates were MuH, and 1 (25%) isolate was MuL. No mupirocin resistance was detected in MSSA. The MuH strains were isolated from the nasal swabs of nursing orderlies whereas the MuL strain was isolated from a nurse.

DISCUSSION {#sec1-4}
==========

Nasal carriage of *S. aureus* acts as an important reservoir of infection among the colonized HCWs and may transmit the infection to co-workers and in the community. The prevalence of *S. aureus* nasal carriage among HCWs is 48% in the present study which is higher than the study conducted by Truong *et al*. (35.8%) and Yazgi *et al*. (34.9%) and comparable to other studies conducted by Singh *et al*. (47.5%) and Al-Abdli and Baiu.\[[@ref10][@ref11][@ref12][@ref13]\] Norazah *et al*., in a study conducted in Malaysia in 2002, reported a higher prevalence of *S. aureus* nasal carriage which varied from 45% to 76%.\[[@ref14]\]

MRSA strains are well known for their high tendency to spread among the HCWs and from the HCWs to the patients which may in-turn lead to the increase in the treatment cost burden by prolonging the duration of hospital stay and or administration of expensive medications. In our study, nasal carriage of MRSA was found in 14% of the HCWs. This is consistent with the study conducted in different hospital setting worldwide which has been reported in the range of 5.8% to 17.8%.\[[@ref15][@ref16][@ref17][@ref18]\] Lower percentage of MRSA carriage has been reported from Nepal.\[[@ref19]\] This difference in prevalence of *S. aureus* and MRSA in various hospitals may be attributed to the inter-laboratory variation in the methods of detection as well as the effectiveness of hospital infection control policy.

In our study, the MRSA carriage was particularly high among the nursing orderlies (6%), which was statistically significant (*P* \< 0.05) \[[Table 2](#T2){ref-type="table"}\]. The higher prevalence of MRSA among this group of HCWs could be due to their lack of knowledge with regard to hand hygiene, contact precautions, and infection control policies.

In this study, all the isolates were susceptible to linezolid. As expected, most of the MRSA isolates were resistant to penicillin. But, the clinically significant observation of the study is the significant association of resistance shown by MRSA to other antibiotics used for the treatment of staphylococcal infections. Other studies report a higher resistance rates for fluoroquinolones and aminoglycosides such as the Pulimood *et al*., that has reported a high ciprofloxacin resistance of 90% and Qureshi *et al*., had reported a resistance of 98.9%.\[[@ref20][@ref21]\] In contrast, this study has demonstrated 50% of the strains resistant to ciprofloxacin and rifampin and a further lower resistant rate to tetracycline (42%) and levofloxacin (21.4%).

Nasal formulation of mupirocin, a topical antibiotic agent that interferes with bacterial protein synthesis, is recommended by the Food and Drug Administration of United States for use in the eradication of nasal carriage of *S. aureus* in adult patients and HCWs. Though the use of mupirocin is limited for infection control and other prophylactic measures, emergence of MupRSA is being reported from across the globe with the prevalence of 0.5% in Nigeria to 14.6% in India.\[[@ref22][@ref23]\] In our study, 4 (2%) isolates were found to be mupirocin resistant of which three isolates were high levels resistant. In the presence of mupirocin resistance strains, treatment with mupirocin may be ineffective, especially with high-level resistance strains. Although low-level mupirocin resistant strains can be controlled by normal dosage schedule of mupirocin but few studies suggest that treatment failure may occur after few weeks. This emphasizes the importance of identification of both high and low-level resistant strains.\[[@ref24][@ref25][@ref26]\]

MRSA nasal colonization of HCWs in our hospital is high, particularly among the nursing orderlies, who are in prolonged contact with the patient leading to the high possibility of nurse-to-patient transmission of these bacteria and dissemination of them in hospital setting. As a routine, screening and treatment of HCWs should be done for MRSA status in every hospital. It is also advisable to detect mupirocin resistance among the isolates obtained from the HCWs so that in case of resistance, alternative treatment options should be initiated.
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